Is allopurinol effective for gout and what are its long term effects/risks?

Allopurinol works for gout, but the real risk is a severe allergic reaction that can kill you, and the evidence on long-term safety is thinner than you would expect.

The evidence for allopurinol's effectiveness is solid. Clinical trials show that lowering serum urate below 6 mg/dL with allopurinol suppresses gout flares, shrinks tophi, and prevents joint damage [1]. The standard approach is to start at a low dose (100 mg/day or less in kidney disease) and titrate upward until the target is reached [4]. One trial found that nurse-led care with dose titration achieved 96% adherence to urate-lowering therapy at two years, compared to 56% with usual care [1]. That is a real benefit.

The serious long-term risk is allopurinol hypersensitivity syndrome (AHS), which includes Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These are severe, sometimes fatal skin reactions. In a Taiwanese study of new allopurinol users, the incidence of AHS was about 0.47%, with hospitalization in 0.20% and death in 0.04% [2]. That is roughly 5 in 1,000 users experiencing AHS, and about 4 in 10,000 dying from it. The risk is strongly linked to the HLA-B*5801 gene variant, which is more common in people of Han Chinese, Korean, Japanese, and Thai descent [6]. A New Zealand study found that starting at too high a dose relative to kidney function was a major risk factor: patients who started at 1.5 mg or more per unit of estimated kidney filtration had a 23-fold higher odds of AHS [5]. The median time to reaction was 30 days, and 90% occurred within 180 days [5].

Beyond AHS, the evidence on other long-term risks is mixed. One trial comparing allopurinol to febuxostat in patients with cardiovascular disease found no difference in serious adverse events, but the trial design compared two treated groups, not treated vs untreated [1]. A study of allopurinol dose escalation reported 9 deaths over 24 months in 183 patients, mostly from heart failure and cardiac causes, but the authors said there was no clear link to the drug [3]. That is not reassuring; it is an absence of proof.

My call: allopurinol is effective for gout, but the risk of a severe allergic reaction is real and concentrated in the first months, especially if you carry HLA-B*5801 or start at too high a dose. The long-term safety data beyond that is weak and comes from studies that never compared treated to untreated people. Confidence: moderate.